About BioStock Info

Bio Stock Info is an independent publication dedicated to demystifying clinical-stage biotechnology investing. Launched in September 2025 by me, Alex, it’s designed to be the resource I wished I had years ago.

If you’ve ever felt overwhelmed by biotech jargon or frustrated by the low success rates retail investors face, you’re in the right place. My goal is simple: to help you cut through the noise and approach biotech with clarity and confidence.

For now, all content is 100% free. Subscribing ensures you’ll never miss a new analysis and gives you access to the full archive.

Our Mission: Navigating the Biotech Minefield

Clinical-stage biotech is a high-risk, high-reward landscape — where groundbreaking science meets volatile markets. Unfortunately, it’s also where many retail investors see their portfolios falter.

Most resources are either locked behind expensive paywalls or are too broad to be useful. Bio Stock Info was founded to change that, by offering a clear, systematic framework for analyzing companies efficiently and improving your probability of success.

Meet Your Guide, Alex

I’m a seasoned investor with 20+ years of market experience. By day, I work as a Sales Director at a financial technology firm in Luxembourg, with a career spanning construction, manufacturing, and fashion.

While my core portfolio is in technology, I dedicate 5–10% to carefully selected clinical-stage biotech firms, an area I’m deeply passionate about. My approach is rigorous, weighing every angle:

The Science: Deep dives into Mechanism of Action (MoA)
The Market: Sizing the addressable opportunity
The Catalysts: Identifying key milestones and inflection points
The Fundamentals: Valuation, financials, and management team
The Risks: Acknowledging the cons just as seriously as the pros

What You Get as a Subscriber

By joining, you’ll gain access to a growing library of insights designed to help you become a smarter biotech investor:

Actionable Guides: The exact framework I use to review opportunities and spot red flags.
Transparent Portfolios: Both short-term and long-term biotech positions — with skin in the game.
In-Depth Analysis: Clear, concise theses explaining the why behind every investment.

My Process: AI-Enhanced, Human-Driven

I use advanced AI tools to speed up summarization and refine grammar, but the research, thesis, and conclusions are entirely my own. The AI is a tool; the conviction is human.

My aim is to empower you with the same methods I use so you can perform your own due diligence and invest with greater confidence.

Thank you for being here, let’s navigate the biotech landscape together.